Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damageNoriaki Arakawa(National Institute of Health Sciences), Masayuki Hanaoka(Shinshu University)Nature CommunicationsOctober 4, 202210.1038/s41467-022-33160-9Cited by 29SaveCiteExport RISWatch citationsRelated PapersClinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma|PLoS ONE|2016|38Stratifin as a Novel Diagnostic Biomarker in Serum for Diffuse Alveolar Damage|Research Square|2021|1